A specially engineered antibody that can infiltrate kidney cysts has shown the ability to block key growth signals driving ...

Polycystic kidney disease (PKD) is a debilitating hereditary condition in which fluid-filled sacs form and proliferate in the ...

PKD is mainly caused by mutations in the PKD1 and PKD2 genes, affecting polycystin proteins. Disrupted signaling pathways, like cAMP and vasopressin, are major drivers of cyst growth. Tolvaptan is ...

Acquired cystic kidney disease represents a condition where fluid-filled sacs (also known as renal cysts) develop in the kidney. These cysts tend to develop in the cortex and medulla regions of the ...

Recent market growth is driven by advancements in understanding disease mechanics, targeted therapies like tolvaptan (Jynarque), and increased diagnosis rates. Tolvaptan, approved by the FDA, marks a ...

The REMODEL trial testing semaglutide’s efficacy in patients with CKD and T2DM also employed MRI, transcriptomics, blood and urine samples, and kidney biopsies to clarify the drug’s effects.

A prolonged course of antibiotic therapy dramatically reduces the risk of recurrence in patients with renal cyst infections in the context of autosomal dominant polycystic kidney disease (ADPKD), a ...

People with polycystic kidney disease (PKD) could benefit from a moderate increase in water intake, according to new research. People with polycystic kidney disease (PKD) could benefit from a moderate ...

Polycystic kidney disease (PKD) causes round, fluid-filled sacs called cysts to grow in your kidneys. These cysts can cause your kidneys to enlarge and function poorly. People with PKD can also ...

Polycystic kidney disease (PKD) is a genetic disorder marked by the growth of many fluid-filled sacs (cysts) in your kidneys. These cysts can grow to replace normal kidney tissue over time, leading to ...